TL;DR
This study investigated whether gout patients have a different risk of non-vertebral fractures compared to rheumatoid arthritis (RA) patients. Using a large Medicare dataset, they found that gout patients had a lower risk of non-vertebral and hip fractures than RA patients, despite both conditions being inflammatory and associated with bone issues. This suggests that while both conditions are serious, their impact on fracture risk may differ.
What Problem Does This Paper Address?
Rheumatoid arthritis (RA) is well-established as a condition that increases the risk of fractures, likely due to chronic inflammation, bone erosion, and the use of treatments like steroids. Gout, another inflammatory arthritis characterized by uric acid crystal deposition, also involves inflammation and can lead to bone damage. However, the relationship between gout and fracture risk has been less clear, with some studies suggesting a protective effect of uric acid on bone density, while others indicate an increased risk. This paper aims to clarify this by directly comparing the fracture risk in gout patients to RA patients, a group with a known higher fracture risk, using a large, real-world dataset.
Methods
The researchers conducted a retrospective cohort study using Medicare claims data from 2008 to 2015. They identified patients with gout and RA, matching them 1:1 based on age, sex, and index date. The primary outcome was a composite of non-vertebral fractures (hip, pelvis, humerus, wrist), with hip fractures analyzed separately. They used multivariable Cox proportional hazards regression to estimate the hazard ratio (HR) for fractures in gout patients compared to RA patients, adjusting for a comprehensive set of 45 covariates. These covariates included demographics, various comorbidities, osteoporosis risk factors, medication use (including steroids and TNF inhibitors), and healthcare utilization.
Datasets
The study utilized longitudinal claims data from Medicare (Parts A, B, and D) for the period between January 1, 2008, and September 30, 2015. This dataset is a large, nationally representative source of health information for US citizens aged 65 and older, as well as younger individuals with certain disabilities. No new datasets were introduced.
Key Insights and Ideas
- Counterintuitive Finding: The most striking insight is that gout patients, despite having inflammatory arthritis, exhibited a lower risk of non-vertebral and hip fractures compared to RA patients. This challenges the assumption that all inflammatory arthritides carry a similar fracture risk profile.
- Comorbidity Differences: The study highlighted distinct comorbidity profiles between the two groups. RA patients were more likely to have osteoporosis and use osteoporosis medications and steroids, while gout patients had higher rates of obesity, frailty, and a broader range of other comorbidities. These differences might contribute to the observed fracture risk disparity.
- High Absolute Fracture Burden: Despite the relative decrease in risk for gout patients, the absolute rates of non-vertebral and hip fractures were still substantial in both gout and RA groups, underscoring the significant fracture burden in older adults with these conditions.
- Importance of Secondary Prevention: The finding that patients with a prior fracture had a similar risk of subsequent fractures in both gout and RA groups emphasizes the critical need for secondary fracture prevention strategies in all patients with inflammatory arthritis, regardless of the specific diagnosis.
Key Results
- The study included 134,157 matched pairs of gout and RA patients, with a mean age of 73.7 years.
- Over a mean follow-up of 2.8 years, the incidence rate (IR) of non-vertebral fractures was 10.42 per 1000 person-years (PY) in gout and 15.01 per 1000 PY in RA.
- The IR of hip fractures was 4.86 per 1000 PY in gout and 7.73 per 1000 PY in RA.
- After adjusting for 45 covariates, the hazard ratio (HR) for non-vertebral fractures in gout compared to RA was 0.84 (95% CI 0.80–0.88).
- The HR for hip fractures in gout compared to RA was 0.76 (95% CI 0.71–0.82).
- All-cause mortality was similar between the two groups.
Limitations and Future Work
The authors acknowledge several limitations:
- Disease Severity and Duration: The claims data did not allow for the assessment of gout or RA disease severity or duration, which could influence fracture risk.
- Serum Urate Levels: The impact of serum urate levels on fracture risk could not be assessed due to the lack of laboratory data.
- Vertebral Fractures: Vertebral fractures were not assessed, as they are difficult to accurately capture in claims data.
- Residual Confounding: Despite adjusting for over 45 variables, residual confounding by unmeasured factors (e.g., BMI, BMD, diet, physical activity) may exist.
- Generalizability: The study population consisted of older Medicare beneficiaries, and the gout cohort had a higher proportion of women than typically seen in general gout populations, requiring careful interpretation of the findings.
- Baseline Period: The 365-day baseline period might not be sufficient to capture all relevant patient characteristics.
Future work could focus on incorporating laboratory data (serum urate), disease activity measures, and potentially using imaging data to better understand the mechanisms behind these observed differences in fracture risk. Further research into the specific role of comorbidities and lifestyle factors in mediating fracture risk in gout versus RA would also be valuable.
Summary updated